| 1661 |
ORSERDU |
ELACESTRANT 345 MG |
TABLET |
BOTTLE |
FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN OR ADULT MEN WITH ESTROGEN RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE, ESR1-MUTATED ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING AT LEAST ONE LINE OF ENDROCRINE THERAPY |
NULL |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS |
CERTIFICATE RELEASED |
11 L 1258/24 |
25-DEC-2024 |
24-DEC-2029 |
View |
| 1662 |
OSIMITINIB |
OSIMERTINIB 80 MG |
TABLET |
BOTTLE |
AS ADJUVANT THERAPY AFTER TUMOR RESECTION IN ADULT PATIENTS WITH NON SMALL CELL LUNG CANCER WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS |
NULL |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS |
CERTIFICATE RELEASED |
03 L 0953/23 |
23-MAR-2023 |
22-MAR-2026 |
View |
| 1663 |
PARATAMOL |
PARACETAMOL 250 MG |
TABLET |
BLISTERPACK |
ANALGESIC/ANTIPYRETIC FOR THE TREATMENT OF MILD PAIN OR FEVER |
NULL |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS |
CERTIFICATE RELEASED |
10 L 0926/22 |
11-Nov-2022 |
10-Nov-2025 |
View |
| 1664 |
PARATAMOL |
PARACETAMOL 500 MG |
TABLET |
BLISTERPACK |
ANALGESIC/ANTIPYRETIC FOR THE TREATMENT OF MILD PAIN OR FEVER |
NULL |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS |
CERTIFICATE RELEASED |
10 L 0927/22 |
11-Nov-2022 |
10-Nov-2025 |
View |
| 1665 |
PARATAMOL COMPOUND |
PARACETAMOL 500 MG, CHLORPHENIAMINE MALEATE 2 MG, PHENYLEPHRINE HCL 10 MG |
TABLET |
BLISTERPACK |
FOR THE RELIEF OF SYMPTOMS CAUSED BY THE COMMON COLD, SINUSITIS, FLU AND OTHER MINOR RESPIRATORY TRACT INFECTIONS, SUCH AS PLUGGED NOSE, HEADACHE, BODY ACHES, AND FEVER. |
NULL |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS |
CERTIFICATE RELEASED |
02 L 0947/23 |
24-FEB-2023 |
23-FEB-2026 |
View |
| 1666 |
PRETOSIS |
PRETOMANID 200 MG |
TABLET |
BOTTLE |
AS PART OF A COMBINATION REGIMEN WITH BEDAQUILINE AND LINEZOLID FOR THE TREATMENT OF ADULT WITH PULMONARY TUBERCULOSIS THAT IS ESISTANT TO ISIONIAZID, RIFAMYCINS, A FLUROQUINOLONE AND A SECOND LINE INJECTABLE ANTIBACTERIAL DRUG OR ADULTS WITH PULMONARY TB RESISTANT TO ISONIAZID AND RIFAMPIN WHO ARE TREATMENT-INTOLERANT OR NONRESPONSIVE TO STANDARD THERAPY. |
NULL |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS |
CERTIFICATE RELEASED |
03 L 1309/25 |
31-MAR-2025 |
30-MAR-2030 |
View |
| 1667 |
SOTOKRAS |
SOTORASIB 120 MG |
TABLET |
BOTTLE |
FOR THE TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE RECEIVED AT LEAST ONE PRIOR SYSTEMIC THERAPY |
NULL |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS |
CERTIFICATE RELEASED |
06 L 0981/23 |
28-JUN-2023 |
27-JUN-2026 |
View |
| 1668 |
TENOFIR-150 |
TENOFOVIR DISOPROXIL FUMARATE 150 MG |
TABLET |
BOTTLE |
TREATMENT OF HIV INFECTION WITH COMBINATION WITH OTHER ANTIVIRALS |
NULL |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS |
CERTIFICATE RELEASED |
11 L 0939/22 |
06-DEC-2022 |
05-DEC-2025 |
View |
| 1669 |
TENOFIR-300 |
TENOFOVIR DISOPROXIL FUMARATE 300 MG |
TABLET |
BLISTERPACK |
TREATMENT OF HIV INFECTION WITH COMBINATION WITH OTHER ANTIVIRALS |
NULL |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS |
CERTIFICATE RELEASED |
12 L 0945/22 |
06-DEC-2022 |
05-DEC-2025 |
View |
| 1670 |
TROMBO |
AVATROMBOPAG MALEATE 20 MG |
TABLET |
BOTTLE |
THROMBOCYTOPENIA IN ADULTS WITH CHRONIC LIVER DISEASE WHO ARE PLAINNING SURGERY, ALSO IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA WHO HAVE HAD AN INADEQUATE RESPONSE TO PRIOR THERAPY |
NULL |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS |
CERTIFICATE RELEASED |
03 L 0951/23 |
27-MAY-2025 |
26-MAY-2030 |
View |
